0001193125-20-315383.txt : 20201211 0001193125-20-315383.hdr.sgml : 20201211 20201211074353 ACCESSION NUMBER: 0001193125-20-315383 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20201211 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201211 DATE AS OF CHANGE: 20201211 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LEXICON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001062822 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 760474169 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30111 FILM NUMBER: 201382251 BUSINESS ADDRESS: STREET 1: 8800 TECHNOLOGY FOREST PLACE CITY: THE WOODLANDS STATE: TX ZIP: 77381 BUSINESS PHONE: 2818633000 MAIL ADDRESS: STREET 1: 8800 TECHNOLOGY FOREST PLACE CITY: THE WOODLANDS STATE: TX ZIP: 77381 FORMER COMPANY: FORMER CONFORMED NAME: LEXICON PHARMACEUTICALS, INC./DE DATE OF NAME CHANGE: 20070426 FORMER COMPANY: FORMER CONFORMED NAME: LEXICON GENETICS INC/TX DATE OF NAME CHANGE: 20000126 8-K 1 d100861d8k.htm 8-K 8-K
false 0001062822 0001062822 2020-12-11 2020-12-11

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 11, 2020

 

 

Lexicon Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-30111   76-0474169

(State or other jurisdiction of

incorporation or organization)

  

(Commission

File Number)

  

(IRS Employer

Identification Number)

8800 Technology Forest Place

The Woodlands, Texas 77381

(Address of principal executive offices and Zip Code)

(281) 863-3000

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

symbol(s)

  

Name of each exchange

on which registered

Common stock, par value $0.001   LXRX   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 8.01

Other Events

On December 11, 2020, we issued a press release announcing that we received Fast Track designation from the U.S. Food and Drug Administration for the development of LX9211 in diabetic peripheral neuropathic pain. The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 and incorporated herein by this reference.

 

Item 9.01

Financial Statements and Exhibits

(d)    Exhibits.

 

Exhibit
Number

   

Description

99.1    Press Release dated December 11, 2020.
EX-104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

      Lexicon Pharmaceuticals, Inc.
Date: December 11, 2020     By:  

/s/ BRIAN T. CRUM

      Brian T. Crum
      Vice President and General Counsel
 EX-99.1 2 d100861dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

NEWS RELEASE

 

FOR IMMEDIATE RELEASE

LEXICON PHARMACEUTICALS RECEIVES FAST TRACK DESIGNATION FROM THE FDA FOR LX9211 FOR DIABETIC PERIPHERAL NEUROPATHIC PAIN

The Woodlands, Texas, December 11, 2020 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the development of LX9211 in diabetic peripheral neuropathic pain.

“The FDA’s Fast Track designation of LX9211 reflects the serious unmet medical need of people suffering from diabetic peripheral neuropathic pain,” said Praveen Tyle, Ph.D., executive vice president of research and development. “We look forward to working closely with the FDA throughout the clinical development process to bring this potential new innovative treatment to patients as quickly as possible.”

Lexicon is currently enrolling patients with diabetic peripheral neuropathic pain in a Phase 2 proof-of-concept study of LX9211 and is preparing to initiate a second Phase 2 clinical trial of LX9211 in post-herpetic neuralgia.

The FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs that are being developed to treat serious conditions and fill unmet medical needs. The purpose of the designation is to expedite the timeline for bringing important new drugs to patients. Programs receiving Fast Track designation may benefit from early and frequent interactions with the FDA over the course of drug development. In addition, the Fast Track designation program provides eligibility for accelerated approval and priority review if relevant criteria are met and enables sponsors to submit individual sections of a New Drug Application (NDA) for review on a rolling-submission basis.

About LX9211

LX9211 is a potent, orally delivered, selective small molecule inhibitor of adapter-associated kinase 1 (AAK1). Lexicon identified AAK1 in its target discovery efforts as a promising approach for the treatment of neuropathic pain, and identified LX9211 and another development candidate in a neuroscience drug discovery alliance with Bristol-Myers Squibb from which Lexicon holds exclusive development and commercialization rights. Preclinical studies of LX9211 demonstrated central nervous system penetration and reduction in pain behavior in models of neuropathic pain without affecting opiate pathways.

About Lexicon Pharmaceuticals

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and

Page 2

development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, heart failure, diabetes and metabolism and other indications. For additional information, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position, long-term outlook on its business and the clinical development and therapeutic and commercial potential of its drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of LX9211, sotagliflozin and its other potential drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

For Inquiries:

Chas Schultz

Executive Director, Corporate Communications and Investor Relations

Lexicon Pharmaceuticals

(281) 863-3421

cschultz@lexpharma.com

EX-101.SCH 3 lxrx-20201211.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 lxrx-20201211_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 lxrx-20201211_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g100861g1210205138904.jpg GRAPHIC begin 644 g100861g1210205138904.jpg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d100861d8k_htm.xml IDEA: XBRL DOCUMENT 0001062822 2020-12-11 2020-12-11 false 0001062822 8-K 2020-12-11 Lexicon Pharmaceuticals, Inc. DE 000-30111 76-0474169 8800 Technology Forest Place The Woodlands TX 77381 (281) 863-3000 false false false false Common stock, par value $0.001 LXRX NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information
Dec. 11, 2020
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001062822
Document Type 8-K
Document Period End Date Dec. 11, 2020
Entity Registrant Name Lexicon Pharmaceuticals, Inc.
Entity Incorporation State Country Code DE
Entity File Number 000-30111
Entity Tax Identification Number 76-0474169
Entity Address, Address Line One 8800 Technology Forest Place
Entity Address, City or Town The Woodlands
Entity Address, State or Province TX
Entity Address, Postal Zip Code 77381
City Area Code (281)
Local Phone Number 863-3000
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common stock, par value $0.001
Trading Symbol LXRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d100861d8k.htm d100861dex991.htm lxrx-20201211.xsd lxrx-20201211_lab.xml lxrx-20201211_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d100861d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d100861d8k.htm" ] }, "labelLink": { "local": [ "lxrx-20201211_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "lxrx-20201211_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "lxrx-20201211.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "lxrx", "nsuri": "http://www.lexpharma.com/20201211", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d100861d8k.htm", "contextRef": "duration_2020-12-11_to_2020-12-11", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d100861d8k.htm", "contextRef": "duration_2020-12-11_to_2020-12-11", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.lexpharma.com//20201211/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001193125-20-315383-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-20-315383-xbrl.zip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end